Search research articles
Contact Us
Filters
Showing results (61-70 of 81) with videos related to
Page
of 9
Sort By:
The Journal of Clinical Investigation
|
March 1, 1995
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter
D Harats, H Kurihara, P Belloni, et al.
Journal of Lipid Research
|
December 8, 2000
LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice
P J Tacken, B Teusink, M C Jong, et al.
Atherosclerosis
|
July 25, 1998
Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis
J George, A Afek, B Gilburd, et al.
Clinical Pharmacology and Therapeutics
|
August 15, 2001
Interindividual variability in sensitivity to warfarin--Nature or nurture?
R Loebstein, H Yonath, D Peleg, et al.
Genes & Cancer
|
June 16, 2012
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models
H V Reddi, P Madde, Y C Cohen, et al.
Circulation
|
October 3, 2001
12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice
J George, A Afek, A Shaish, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
October 2, 2004
Overexpression of 15-lipoxygenase in the vascular endothelium is associated with increased thymic apoptosis in LDL receptor-deficient mice
A Afek, N Zurgil, Y Bar-Dayan, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
January 5, 1999
Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice
A Afek, J George, Y Shoenfeld, et al.
Human Antibodies
|
July 16, 1999
Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events
J George, A Aron, Y Levy, et al.
Diabetes, Obesity & Metabolism
|
January 25, 2003
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model
Z Levi, A Shaish, N Yacov, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 81) with videos related to
Sort By:
Page
of 9
The Journal of Clinical Investigation
|
March 1, 1995
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter
D Harats, H Kurihara, P Belloni, et al.
Journal of Lipid Research
|
December 8, 2000
LDL receptor deficiency unmasks altered VLDL triglyceride metabolism in VLDL receptor transgenic and knockout mice
P J Tacken, B Teusink, M C Jong, et al.
Atherosclerosis
|
July 25, 1998
Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis
J George, A Afek, B Gilburd, et al.
Clinical Pharmacology and Therapeutics
|
August 15, 2001
Interindividual variability in sensitivity to warfarin--Nature or nurture?
R Loebstein, H Yonath, D Peleg, et al.
Genes & Cancer
|
June 16, 2012
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models
H V Reddi, P Madde, Y C Cohen, et al.
Circulation
|
October 3, 2001
12/15-Lipoxygenase gene disruption attenuates atherogenesis in LDL receptor-deficient mice
J George, A Afek, A Shaish, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
October 2, 2004
Overexpression of 15-lipoxygenase in the vascular endothelium is associated with increased thymic apoptosis in LDL receptor-deficient mice
A Afek, N Zurgil, Y Bar-Dayan, et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology
|
January 5, 1999
Enhancement of atherosclerosis in beta-2-glycoprotein I-immunized apolipoprotein E-deficient mice
A Afek, J George, Y Shoenfeld, et al.
Human Antibodies
|
July 16, 1999
Anti-cardiolipin, anti-endothelial-cell and anti-malondialdehyde-LDL antibodies in uremic patients undergoing hemodialysis: relationship with vascular access thrombosis and thromboembolic events
J George, A Aron, Y Levy, et al.
Diabetes, Obesity & Metabolism
|
January 25, 2003
Rosiglitazone (PPARgamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model
Z Levi, A Shaish, N Yacov, et al.
Page
of 9